等待開盤 04-10 09:30:00 美东时间
0.000
0.00%
Organogenesis stock rises after PuraPly AM trial shows improved diabetic foot ulcer closure; RSI signals oversold levels amid weak trend.
04-08 22:15
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports
04-07 05:37
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Buy and maintains $8 price target.
03-26 17:43
Organogenesis Director Arthur S Leibowitz Acquires Common Shares Arthur S. Leibowitz, a director of Organogenesis Holdings Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technolo
03-12 09:46
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and lowers the price target from $9 to $8.
02-27 18:35
Organogenesis Holdings (NASDAQ:ORGO) sees FY2026 sales of $350.000 million-$420.000 million vs $543.400 million analyst estimate.
02-27 05:26
Organogenesis Holdings (NASDAQ:ORGO) reported its Q4 earnings results on Thursd...
02-27 05:26
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11